Medicamen Biotech vs Peers
- Market cap
- ₹413 crore
- P/E
- 22.5
- P/B
- 2.85
- ROE
- 14.5%
- Dividend yield
- 1.20%
- 52-week range
- ₹219.46 – ₹411.48
Medicamen Biotech ranks 1st by market capitalisation among 1 Drug Manufacturers - Specialty & Generic companies tracked by ATS. Its largest peers are Medicamen Biotech. Its P/E of 22.5 compares with a peer median of 22.5.
Medicamen Biotech vs Drug Manufacturers - Specialty & Generic peers
Sorted by market capitalisation.
| Company | Close (₹) | 1D | Market cap (₹ cr) | P/E | P/B | ROE | 1Y return |
|---|---|---|---|---|---|---|---|
| Medicamen Biotech | 304.80 | -2.70% | 413 | 22.5 | 2.85 | 14.5% | +18.5% |
| Medicamen Biotech | 304.80 | -2.70% | 413 | 22.5 | 2.85 | 14.5% | +24.5% |
Source: NSE end-of-day prices; ratios from company filings. Data as of 9 October 2026. How this data is compiled.
Medicamen Biotech peer comparison — frequently asked questions
Who are Medicamen Biotech's competitors?
Medicamen Biotech's listed peers in Drug Manufacturers - Specialty & Generic include Medicamen Biotech, ranked here by market capitalisation.
How does Medicamen Biotech's P/E compare with its peers?
Medicamen Biotech trades at a P/E of 22.5, against a median of 22.5 across the 1 Drug Manufacturers - Specialty & Generic peers shown.
Which is the largest company among Medicamen Biotech's peers?
By market capitalisation, the largest company in the group is Medicamen Biotech at ₹413 crore, against ₹413 crore for Medicamen Biotech.
Same Data For Peers
Trade Medicamen Biotech With ATS
Track MEDICAMEQ live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.